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Abstract
Background Brain laser interstitial thermal therapy (LITT)
under magnetic resonance imaging (MRI) guidance has
recently gained US clinical approval for the ablation of
soft, neurological tissue. LITT is a minimally invasive
alternative to craniotomy.
Objective While safety and efficacy are the focus of most
current LITT studies, it is unclear how acute care costs
(inpatient care ± aftercare) of LITT compare to craniotomy in an academic medical center. Therefore, the
purpose of this analysis is to examine these costs of using
brain LITT under MRI guidance compared to craniotomy
in complex anatomies.
Methods Consecutive patients treated at a single US center
from 1 January 2010 to 21 October 2014 were retrospectively evaluated. Patients were included if they had a primary procedure for LITT or craniotomy (International
Classification of Diseases, 9th revision, Clinical
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Modification [ICD-9-CM] procedure code 17.61 or ICD-9CM procedure code 01.59, respectively) and were subgrouped according to their diagnosis of primary brain or
metastatic brain cancer (ICD-9-CM 191.0–191.9 or ICD-9CM 198.3, respectively). Patients were excluded if they
had co-morbid conditions such as brain edema (ICD-9-CM
348.5). Patients were matched (LITT vs. craniotomy) based
on diagnosis. Appropriate statistical analyses were undertaken to examine the year 2015 costs for care in all settings
(acute hospital and post-hospital care, i.e., skilled nursing
facility, rehabilitation, and home care) were examined.
Results In patients treated for a primary brain cancer, there
was no statistical difference in the acute and post-care costs
of LITT and craniotomy (inverse variance, mean difference
[MD], random effects model): MD = -US$1669; 95%
confidence interval (CI) -$8192 to $4854; P = 0.62.
When examining difficult to access primary malignancies,
no difference was found: MD = -US$4719; 95% CI $12,183 to $2745; P = 0.22. In metastatic brain cancer,
LITT was found to be significantly less costly than craniotomy: MD = -US$6522; 95% CI -$11,911 to -$1133;
P = 0.02.
Conclusions In patients with metastatic brain cancer, LITT
is less costly than craniotomy. Patients receiving LITT had
a significantly shorter length of hospital stay, were significantly older, and were more likely to be discharged home.
The use of LITT may be a reasonable option in bundled
episodes of care for brain cancer and may fit into the
Bundled Payment for Care Improvement (BPCI) program
being evaluated by Medicare and providers.
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Key Points for Decision Makers
Minimally invasive brain cancer surgery, such as
laser interstitial thermal therapy (LITT) may lessen
the need for aftercare compared with that following
more invasive surgeries.
Patients who are diagnosed with brain cancer
generally have a poor prognosis and would likely
prefer to spend the remainder of their lives at home.
Minimally invasive surgery may offer this as a
higher percentage of patients were discharged home
versus craniotomy.
Minimally invasive brain surgery (LITT) may offer
the opportunity to provide a bundle of care (hospital
plus aftercare, e.g., comprehensive care for a 90-day
period) and save the healthcare system money. These
types of bundles are gaining acceptance under the
Affordable Care Act initiatives for novel care
delivery and payment models.

1 Introduction
In the USA, there were 33,455 patients treated for primary
brain cancer (International Classification of Diseases, 9th
revision, Clinical Modification [ICD-9-CM] 191.0–191.9
[1]) in the year 2012 [2]. Using Medicare costs, the estimated inpatient acute care costs for treating these patients
was US$24,290 [2]. Of these patients, approximately 25%
were discharged to either a skilled nursing facility (SNF) or
inpatient rehabilitation facility (IRF), with an additional
15% discharged to home healthcare [2]. Additionally, for
the same year, there were 43,175 patients treated for
metastatic brain cancer (ICD-9-CM 198.3) [2]. The estimated inpatient acute care costs for treating these patients
was US$16,210 [2]. Similarly, approximately 25% were
discharged to either an SNF or IRF, with an additional 22%
discharged to home healthcare [2]. The average estimated
reimbursement rates for an IRF approach US$23,000 [3],1
for an SNF they are US$4900,2 and for home healthcare
they are US$159/day.3 Thus, these patients can cost the
healthcare system significant amounts of money once acute
inpatient and aftercare costs are combined. Additionally,
patients who undergo complex craniotomy procedures
1

Case mix group 302 for non-traumatic brain injury incurred during
neurosurgery procedure. Assumes a length of stay of 12–16 days.
Derived from Federal Register. 2014 Aug 6;79(151):45888 [3].
2
Derived from 2015 Medicare rates in caring for a person post-brain
surgery in an SNF.
3
Medicare daily rate for the 2015 financial year.
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(e.g., excisional surgery in or near sensory/motor areas
[areas of eloquence] or deep-seated tumors) can incur
complication rates of upwards of 15% [4–6], which commonly result in the need for aftercare in such settings as an
SNF or IRF. It is thus important to identify therapies that
can be used in treating complex anatomy, in order to
reduce complications and associated care (and costs) periand post-procedure. A new technology, brain laser interstitial thermal therapy (LITT) under magnetic resonance
imaging (MRI) guidance for treating these types of tumors
has recently been introduced into the USA [7, 8]. In published data, the results have been found to minimize
complications, most especially in complex anatomy [9].
The purpose of this current analysis is to examine the costs
of using brain LITT under MRI guidance compared to
craniotomy in these types of complex anatomies. US academic medical centers have incorporated LITT as an option
in brain tumor surgery, especially in brain tumors where
traditional surgeries such as craniotomy cannot access the
tumor adequately due to its location in or near areas of
eloquence or due to its difficult to access (DTA) and/or
deep-seated nature. It has been found that LITT may
reduce complications while at the same time resecting
more of the tumor. Both of these factors are correlated to
extending the lifespan of patients [10]. Medicare has
recently introduced a Bundled Payment for Care
Improvement (BPCI) program [11], which evaluates therapies over extended bundles of care (e.g., hospital care plus
rehabilitation, nursing, and home care over a 90-day period) and pays for them as such. Thus, care provided and its
associated costs post-hospital discharge will become an
important component of the patient’s overall care. LITT
may fit into this treatment paradigm based on shorter
hospital stays [12].
Lastly, this analysis examines risk factors for complications such as post-operative hospital stay and its association with venous thromboembolism (VTE). It has been
found that, on average, patients who develop VTE stay in
the hospital for 7.7 days post-operatively compared with
6.1 days in those with no VTE diagnosed [13].

2 Methods
Consecutive patients treated at Barnes Jewish Hospital in
St. Louis, MO, USA between 1 January 2010 and 21 October 2014 were retrospectively reviewed to identify those
with a diagnosis code of either ICD-9-CM 191.0–191.9
(malignant neoplasm of the brain) or 198.3 (secondary/
metastatic malignant neoplasm of the brain). Only patients
with brain LITT (ICD-9-CM 17.61) or craniotomy (ICD-9CM 01.59) were included in the analysis. The analysis was
limited to only include patients with co-morbidities
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because this is the subset of patients we hypothesized were
most likely to be treated with LITT. Health records were
reviewed for diagnosis-related group (DRG) 25 (craniotomy and endovascular intracranial procedures with
major complications) and DRG 26 (craniotomy and
endovascular intracranial procedures with complications).
However, the methods were revised as the analysis began
to only include subjects assigned to DRG 26 due to the
limited sample size of DRG 25 (n = 4) within the LITT
cohort. After 2013, LITT as the principal procedure (ICD9-CM 17.61) was used in the vast majority of patients
assigned to DRG 26. Therefore, a before and after analysis
could be performed on similar type patients in a craniotomy versus LITT analysis (with the craniotomy group
largely being treated prior to 2013). The groups were then
subgrouped according to their diagnosis of primary brain or
metastatic brain cancer (ICD-9-CM 191.0–191.9 or 198.3,
respectively). Subjects were further subgrouped by lesion
location. If the lesion was located in or near areas of eloquence (sensory/motor) and deep-seated in nature they
were determined to be ‘DTA.’ DTA lesions were physician-determined.
All costs were examined during the peri- and post-procedure period if they included inpatient surgery and stay
and discharge to another site of care service (i.e., IRF, SNF,
home healthcare, hospice, or readmittance due to complications resulting from the procedure). Costs for inpatient
care were converted from charge to costs (using the institution-specific cost to charge ratio of 0.362). The institution-specific cost to charge ratio is calculated by Medicare
for every hospital that is eligible to treat Medicare patients
(i.e., the vast majority of US hospitals). As an example, for
every US$1000 of charges submitted on a claim form by
Barnes Jewish Hospital, it costs Barnes US$362 to deliver
these services (US$1000 9 0.362 = US$362). These costs
were reflective of the year in which they were incurred and
were adjusted based on medical site-specific Consumer
Price Index (CPI) inflation factors [14] to the year 2015.
For additional site of service care, the specific 2015
Medicare reimbursement rate was adjusted for cost. It was
assumed that patients were classified under Case Mix
Group (CMG) 302 (Non-traumatic brain injury, due to
surgery, Tier 1) for IRF care. For the year 2015 at Barnes
Jewish Hospital, this reimbursement rate was estimated to
be US$24,440 (after adjustments for wages, low-income
patients, and teaching). This also assumes an average
length of stay (ALOS) of 13 days for IRF care based on
Medicare data [15]. It was further assumed that the costs for
type of IRF setting were 99.7% of the reimbursement level
based on Medicare data for IRFs, or a cost of US$24,367
[16]. Further, it was estimated that the reimbursement for
SNF care was US$4284. This was calculated as follows:
first, it was assumed that these patients would require ultra-
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high rehabilitation and would fall under resource utilization
group (RUG) code RUC. The ALOS for this group in the
St. Louis (MO, USA) area for 2014 was 26 days [17]. This
26-day ALOS was input into an SNF calculator, as well as
St. Louis wage-specific indexes being used. Using these
variables, the amount was calculated to be US$4930 for the
2015 calendar year [18]. This reimbursement rate was then
adjusted for cost using a cost to reimbursement ratio of
86.9% [19], resulting in a cost of US$4284. Lastly, home
healthcare was assumed to be at a full episode of
care/payment. The patient discharged to home healthcare
was classified as having high clinical, high functional, and
high service resources, or C3F3S3 (CMS payment group
10333), with a case mix weight of 1.183. For the St. Louis
area, at a non-routine add-on supply severity of ‘3’, the
reimbursement level for the 2015 financial year is US$3471
[20]. This reimbursement rate was then adjusted for cost
using a cost to reimbursement ratio of 87.3% [21], resulting
in a cost of US$3030. Each of these adjusted costs were
used as proxies for the overall cost for care of a patient,
depending upon whether follow-on care was required.
2.1 Statistical Analysis
The analysis of costs were evaluated to determine whether
the aggregate costs for acute care (inpatient stay ± aftercare) were statistically different from each other using the
inverse variance, mean difference (MD), random effects
with 95% confidence interval (CI) analysis method. Significant cost outliers were excluded from this analysis if
they were determined to be outliers using Grubb’s test
P \ 0.05 for outlier identification [22]. Grubb’s test was
used with the understanding that these data came from a
normally distributed population. Ages of the patients were
also evaluated at baseline to determine if there was a statistical difference. Further, an analysis of the incidence of
the aftercare required (by site and in aggregate for 30-day
readmissions, IRF, SNF, and home care) was also examined using a Mantel–Haenszel random effects risk ratio
(RR) analysis with 95% CIs [23]. Summary statistics on
length of stay (LOS) were also analyzed using the mentioned statistical methods. Lastly, a sensitivity analysis was
performed on post-discharge total IRF costs of ± 25% of
the amount used in the analysis (US$24,367; range of
US$18,275 to US$30,459) as these costs were the largest
cost driver of care outside of the hospital.

3 Results
The dataset provided by Barnes Jewish Hospital originally
contained 60 patients treated with LITT and 507 patients
treated with craniotomy (Fig. 1); however, in order to
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Reason for exclusion

60 Paents
Receiving LITT
(ICD9CM 17.61)

507 Paents
Receiving Craniotomy
(ICD9CM 01.59)

Reason for exclusion

LITT was not the
primary procedure
(21 Paents)

Craniotomy was
not the primary
procedure
(16 Paents)

No co-morbidity or
limited sample size*
(9 Paents)

No Co-morbidity
or DRG 25†
(150 Paents)

Cost Outliers
(3 Paents)

Cost Outliers
(1 Paent)

*DRG 25 was excluded
due to low sample size
N=4.

27 LITT subjects
(19 primary brain
cancer, 8 brain
metastac cancer)

340 Craniotomy
subjects (248 primary
brain cancer, 92 brain
metastac cancer)

†DRG 25 was excluded due
to inability to match
paents to LITT for
stascal purposes.

Fig. 1 Subject inclusion/exclusion flow chart: consecutive patients
treated at Barnes Jewish Hospital in St. Louis, MO, USA between
1 January 2010 and 21 October 2014 under ICD-9-CM 191.0–191.9
(malignant neoplasm of the brain) or 198.3 (secondary/metastatic
malignant neoplasm of the brain). Subjects were reviewed for DRGs

25 and 26. Only subjects with DRG 26 were included in subgroup
analyses due to a low sample size for DRG 25 within the LITT cohort.
Cost outliers were excluded from the analysis. DRG diagnosis-related
group, ICD-9-CM International classification of diseases, 9th revision,
clinical modification, LITT laser interstitial thermal therapy

make a side-by-side comparison with LITT and craniotomy, subjects were excluded based on the criteria
described in Sect. 2. Within the LITT cohort, 33 patients
were excluded. Twenty-one were excluded because LITT
was not the principal or only procedure and nine LITT
patients did not exhibit a co-morbidity (DRG 25 or DRG
26)4 or represented a very small number of patients with a
major co-morbidity and/or complication [4]—because only
four LITT patients reported DRG 25 (major complications), they were excluded from further subgrouping. Three
LITT subjects were determined to be cost outliers5 (based
on Grubbs test) (Fig. 2). Thus, 27 LITT patients remained,
of whom 19 were diagnosed with primary brain cancer and
co-morbidity (ICD-9-CM diagnosis 348.5) and eight with a
diagnosis of metastatic brain cancer (ICD-9-CM 198.3).
The baseline characteristics of the patients are shown in
Table 1. In the vast majority of cases, these cancerous
lesions, determined to be ‘DTA’ (for both LITT and
craniotomy), were supratentorial in nature and were located
in the frontal, parietal, and temporal lobes of the brain.

different for primary (ICD-9-CM 191.0–191.9) plus secondary or metastatic brain tumors (ICD-9-CM 198.3) (see
Table 2; Fig. 3). One caveat is that two outliers were
removed for the ICD-9-CM 191–191.9 diagnoses with
LITT. With the outliers included in these diagnoses the
average/standard deviation for costs with LITT were
US$40,729 ± 26,624, and with the outliers excluded the
costs were US$33,392 ± 12,773.
The ages of the patients with primary brain tumors were
statistically different from the older patients in the LITT
group versus craniotomy (58.7 ± 12 years vs. 51 ±
15.5 years, respectively; P = 0.008) (Table 2). In examining the costs in DTA primary tumors (ICD-9-CM
191.0–191.9), the costs for treating patients using LITT
versus craniotomy were not statistically different (see
Table 2; Fig. 3). The ages of these DTA patients were found
to be statistically different (57 ± 12 years for LITT and
49 ± 14 years for craniotomy; P = 0.01). The costs were
further separated by site of service (hospital, SNF, IRF, home
care, readmissions) (Table 3). In treating metastatic brain
cancer (ICD-9-CM 198.3) there was a statistical difference in
costs favoring LITT (see Table 2; Fig. 3). However, when
outliers were included in the metastatic brain cancer group,
the costs were not statistically different: MD = -US$1169;
95% CI -14,757 to 17,095; P = 0.89. The ages of the
patients in the metastatic brain cancer groups were not statistically different from each other.
A sensitivity analysis was performed on the costs for
IRF with craniotomy assuming total IRF costs of ± 25% of
the amount used in the analysis of US$24,367 (range of

3.1 Costs
After removing outliers and aggregating patients by diagnosis and treatment method, the costs for treating patients
using LITT versus craniotomy were not statistically
4

Medicare daily rate for the 2015 financial year.
Derived from 2015 Medicare rates in caring for a person post-brain
surgery in an SNF.

5
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25
20
15
10
5
0

*Outliers were
$98,637
$106,954
$113,900

$20,033
Craniotomy†
Frequency

Fig. 2 Distribution of
procedure costs for LITT and
craniotomy. Actual cost data
were analyzed and clustered by
frequency using ExcelÒ data
analysis ToolPak and Grubb’s
test. Actual costs of outliers are
presented. LITT laser interstitial
thermal therapy

LITT*
Frequency
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$38,806

$57,580

$76,353

120
100
80
60
40
20
0

US$18,275 to US$30,459). We focused on this cost as it
was the highest of the post-hospital site of care services
costs. Specifically, there was a statistically significant difference identified earlier favoring LITT in ICD-9-CM
198.3. Using these IRF ranges lowered the overall costs for
craniotomy to US$34,353 ± 18,661 (P = 0.06) (IRF at
US$18,275 or 75% of the estimated costs used in the
model) and increased overall costs for craniotomy to
US$37,530 ± 22,147 (P = 0.002) (IRF at US$30,459 or
125% of the estimated costs used in the model).
Although there was a limited sample size within
DRG 25 for the LITT cohort (n = 4) and this group was
excluded from further subgroup analyses, we did look at
average costs between craniotomy and LITT patients.
Major complications were experienced by 150 craniotomy
patients and brain edema was the complication reported in
the majority of patients. The costs for craniotomy procedures were on average US$50,090 ± 26,967. Of these
patients, 43% went to a SNF after the procedure. There
were no outliers within the craniotomy cohort for DRG 25.
Four LITT patients mapped to DRG 25 and there was high
variability,
with
the
average
costs
being
US$85,375 ± 33,155.
3.2 Incidence of Aftercare and Readmissions
After removing all outliers, the incidence of discharge to
other sites of service (IRF, SNF, and home healthcare) was
significantly higher with craniotomy when examining all
patients treated for primary and metastatic tumors:
RR = 0.28; 95% CI 0.11–0.71; P = 0.007 (Fig. 4). These
data indicate that patients were more likely to be discharged home with LITT than with craniotomy. For the
most expensive site of service, IRF, there was no difference
in the incidence of discharge to this care site for both

$95,127

†Outlier was
$132,368

primary and metastatic tumors: RR = 0.80; 95% CI
0.35–1.80; P = 0.59. Further, for the incidence of 30-day
readmissions, there was no statistical difference between
LITT and craniotomy: RR = 0.12; 95% CI 0.01–1.94;
P = 0.14.
Twenty-five of 92 patients in the craniotomy group were
readmitted for diagnosis of metastatic tumor versus zero of
eight patients with LITT. These craniotomy readmissions
added an average of US$3400 to the overall cost of care,
with craniotomy averaging US$35,941 ± 20,301. Without
these readmissions there would have been no statistically
significant difference between craniotomy and LITT.
3.3 Length of Stay
The average length of stay (ALOS) for all diagnoses
included within primary tumor and metastatic tumor was
statistically different (P \ 0.00001), favoring LITT
(Table 4) with an ALOS of 2.33 ± 2.13 days versus an
ALOS of 4.71 ± 3.16 days for craniotomy. This statistically meaningful difference remained when diagnoses were
separated into the diagnoses of primary tumor and metastatic tumor. In an examination of each diagnosis by
treatment type, the average/standard deviation for costs and
LOS remained fairly consistent amongst each diagnosis
(ICD-9-CM 191–191.9) for craniotomy. There were similar
findings with LITT for each diagnosis.
Post-operative LOS is a risk factor for venous thromboembolism (VTE) [12]. Table 5 shows the number of
VTE events along with the number of patients by diagnosis
who had an ALOS of[7.7 days and those with an ALOS of
\6.1 days. Two of 27 (7%) patients exceeded the 7.7-day
ALOS in the LITT group and 43 of 340 (13%) exceeded it
in the craniotomy group; this difference was not statistically different (Table 5). It should be noted that one of the
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Table 1 Baseline characteristics and discharge disposition
Characteristic

LITT

Craniotomy

Number of patients

19

248

Age (years) [mean ± SD (range)]

57.53 ± 12.05 (35–81)

51.73 ± 15.47 (22–85)

M/F (n)

14/5

148/100

Malignant neoplasm of cerebrum (191)

2 (10)

3 (1)

Malignant neoplasm frontal lobe (191.1)

9 (47)

101 (41)

Malignant neoplasm of temporal lobe (191.2)

2 (10)

76 (31)

Malignant neoplasm of parietal lobe (191.3)

1 (5)

27 (11)

Primary brain cancers (ICD-9-CM diagnosis 191.0–191.9)

Diagnosis breakout [n (%)]

Malignant neoplasm of occipital lobe (191.4)

1 (5)

13 (5)

Malignant neoplasm of ventricles (191.5)
Malignant neoplasm of cerebellum NOS (191.6)

1 (5)
0

5 (2)
5 (2)

Malignant neoplasm of brain stem (191.7)

0

0

Malignant neoplasm of other parts of brain (191.8)

2 (10)

14 (6)

Malignant neoplasm of brain, unspecified (191.9)

1 (5)

4 (2)

Number of 30-day readmissions [n (%)]

0

31 (13)

Home

15 (79)

163 (66)

IRF

3 (16)

54 (22)

SNF

0

3 (1)

Home healthcare

1 (5)

28 (11)

Discharged to [n (%)]

Metastatic brain cancer (ICD-9-CM diagnosis 198.3)
Number of patients

8

92

Age (years) [mean ± SD (range)]

58.73 ± 9.65 (40–67)

61.98 ± 10.23 (29–81)

M/F (n)

5/3

40/52

Number of 30-day readmissions [n (%)]

0

17 (18)

Discharged to [n (%)]
Home

8 (100)

51 (55)

IRF

0

25 (27)

SNF

0

3 (3)

Home healthcare

0

13 (14)

F female, ICD-9-CM International classification of diseases, 9th revision, clinical modification, IRF inpatient rehabilitation facility, LITT laser
interstitial thermal therapy, M male, NOS not otherwise specified, SD standard deviation, SNF skilled nursing facility

four patients with primary/metastatic tumor and craniotomy where VTE was diagnosed (and required a readmission) had an ALOS exceeding 7.7 days.

4 Discussion
LITT is a relatively new technology and the majority of the
current publications relating to LITT focus on the safety
and efficacy of the device. Previous studies using cost
modeling showed that LITT is cost effective compared to
craniotomy [24]. This study attempted to decipher the early
economic picture of LITT using actual cost data from a
teaching hospital and aimed to understand patient outcomes as they relate to location of discharge.

In the comparison of LITT and craniotomy procedures
performed in areas that were DTA or in areas of eloquence,
the peri- and post-procedural costs are significantly less
with LITT than with craniotomy for metastatic tumors but
are not statistically different in primary tumors. When DTA
tumors were examined in aggregate (metastatic plus primary), there was no statistical difference in the overall
costs, despite costs being lower by US$4700 in the LITT
group versus craniotomy. This non-statistically different
finding was likely due to the small numbers of patients in
the LITT group (n = 19). The older age of LITT patients
may have also adversely affected the costs as increasing
age is a risk factor for unfavorable post-operative outcomes
(and costs associated with treating them) in patients with
brain tumors [25]. Thus, the statistically significant finding
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Table 2 Cost comparison by tumor type and procedure type
Tumor typea

Procedure

Average costs
(US$)b

Statistical findings

Primary and metastatic
(n = 27)

Brain LITT

32,215 ± 11,891

MD = –US$2767; 95% CI –7639 to 2105;
P = 0.27

Primary and metastatic
(n = 340)

Craniotomy

34,982 ± 17,903

Primary only (n = 19)

Brain LITT

33,392 ± 13,773

Primary only (n = 248)

Craniotomy

35,061 ± 16,471

Metastatic only (n = 8)

Brain LITT

29,419 ± 4965

Metastatic only (n = 92)

Craniotomy

35,941 ± 20,401

DTA (n = 19)

Brain LITT

33,392 ± 13,773

DTA (n = 65)

Craniotomy

38,111 ± 17,139

Average age
(years)
57.8 ± 11.2
54.5 ± 14.9
58.71 ± 12c

MD = –US$1669; 95% CI –8192 to 4854;
P = 0.62

51 ± 15.5c

MD = -US$6522; 95% CI -11,927 to -1117;
P = 0.02
MD = -US$4719; 95% CI -12,183 to 2745;
P = 0.22

59 ± 9.6
62 ± 10
57 ± 12d
49 ± 14d

CI confidence interval, DTA difficult to access, ICD-9-CM International classification of diseases, 9th revision, clinical modification, LITT laser
interstitial thermal therapy, MD mean difference
a

Primary tumors: ICD-9-CM diagnosis codes 191.0–191.9 (malignant neoplasm of the brain); secondary tumors: ICD-9-CM diagnosis code
198.3 (secondary malignant neoplasm, brain and spinal cord)

b

Average costs: average costs of procedure and post-acute care, which includes skilled nursing facility, inpatient rehabilitation facility, and/or
home care

c

Significant at the P = 0.008 level

d

Significant at the P = 0.01 level

Fig. 3 Average costs (in US
dollars) of acute care by tumor
and procedure type, including
surgery and postoperative care.
CI confidence interval, LITT
laser interstitial thermal therapy

$40,000
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of the older age of LITT patients may have increased the
costs for this group. Lastly, DTA tumors have been found
to have higher complication rates than non-DTA tumors
[26–31] and there may be a major difference in the complication rate favoring lower complications with LITT [23].
The incidence of post-procedural discharge to other sites of
care was also found to be significantly higher with craniotomy for primary and metastatic brain cancer. This is an
important finding in that one might assume that since brain
LITT is being utilized in more challenging anatomy (relative to craniotomy), the complication rates, and hence the
incidence of post-procedural care, could potentially be
higher, including from a cost standpoint; however, this was

not the case. The minimally invasive nature of brain LITT
(relative to an open craniotomy) likely reduces the collateral damage of the treatment of the tumor and reduces the
global stress on the patient, which translates to a more
rapid and functional discharge. Complication rates with
craniotomy have been noted to be in the 11–21% range in
large series of patients [4, 32–34], with most patients
experiencing complications likely to require follow-on
care. This higher complication rate was found despite
intraoperative imaging (MRI and ultrasound) being used
with craniotomy to help guide clinicians [4, 23, 32].
Complications seen with craniotomy can also affect any
adjunctive therapy that might be needed to improve overall
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Table 3 Breakdown of average costs by site of service
Tumor type

Procedure

Inpatient
(US$)

30-day
readmittance (US$)

IRF and/or SNF
(US$)

Primary only
(n = 19)

Brain LITT

29,386

0

3847

Primary only
(n = 248)

Craniotomy

27,726

1636

Metastatic only
(n = 8)

Brain LITT

29,419

Metastatic only
(n = 92)

Craniotomy

25,349

IRF and/or SNF
readmittance (US$)

Home care
(US$)

Total
(US$)

0

159

33,392

4964

466

269

35,061

0

0

0

0

29,419

3402

6403

358

428

35,941

DTA (n = 19)

Brain LITT

29,386

0

3847

0

159

33,392

DTA (n = 65)

Craniotomy

28,910

3251

4874

750

326

38,111

DTA difficult to access, IRF inpatient rehabilitation facility, LITT laser interstitial thermal therapy, SNF skilled nursing facility

Fig. 4 Forest plot: incidence of discharge to other sites of service, including inpatient rehabilitation facility, skilled nursing facility, and home
healthcare. CI confidence interval, LITT laser interstitial thermal therapy, M-H Mantel–Haenszel
Table 4 Average length of stay for ICD-9-CM codes 191.0–191.9 and 198.3 (analysis method: inverse variance, mean difference, random
effects)
Primary
procedure

Number of
patients

LITT (17.61)
Craniotomy (01.59)

ALOS
(days)

ALOS
(SD)

Findings

Average age (years) ±
SD (P = 0.15)

MD = -2.38; 95% CI -3.25 to -1.51; P \ 0.00001

57.8 ± 11.2

27

2.33

2.13

340

4.71

3.16

54.5 ± 14.9

ALOS average length of stay, CI confidence interval, ICD-9-CM International classification of diseases, 9th revision, clinical modification, LITT
laser interstitial thermal therapy, MD mean difference, SD standard deviation
Table 5 Length of stay for ICD-9-CM codes 191.0–191.9 and 198.3 for those with a length of stay [7.7 and \6.1 days and the incidence of
venous thrombosis post-procedure
Primary
procedure
LITT
(17.61)
Craniotomy
(01.59)

Number of
patients

ALOS (days)
(mean ± SD)

Number of patients with an
LOS [7.7 days [n (%)]

Number of patients with an
LOS \6.1 days [n (%)]

Incidence of VT (in those
with LOS [7.7 days)

27

2.33 ± 2.13

2 (7)

25 (93)

0

340

4.71 ± 3.16

43 (13)

274 (81)

1

ALOS average length of stay, ICD-9-CM International classification of diseases, 9th revision, clinical modification, LITT laser interstitial thermal
therapy, LOS length of stay, SD standard deviation, VT venous thrombosis

survival [32]. While there was no statistical difference in
the incidence of 30-day readmissions between LITT and
craniotomy in primary cancers (ICD-9-CM 191-191.9), it
should be noted that none (out of 27) occurred in LITT
while 44 (out of 340) occurred in craniotomy. In sensitivity

analysis it was found that these additional costs had an
effect on the statistically significant difference in costs seen
between LITT and craniotomy for metastatic disease (in
which 17 of the 44 thirty-day readmissions for craniotomy
occurred), adding, on average, US$3400/patient for the
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patients evaluated for this condition. Thus, readmissions
appear to be an issue that is more associated with
craniotomy.
As can be seen from the data, patients in the LITT
group had an ALOS of approximately 2.3 days versus
4.7 days for craniotomy; this difference was statistically
different. The incidence of VTE in the diagnoses analyzed
for primary and metastatic tumor was four of 340 patients
in the craniotomy group versus no patients of 27 in the
LITT group. It should be noted that LOS as a risk factor
for VTE was minimized with LITT compared to craniotomy. Specifically, as it relates to VTE, three of the
VTE patients in the craniotomy group had an LOS of
2–3 days. There are other risk factors that were present
(other than an LOS [7.7 days) that may have caused
these VTEs, such as a metastatic brain lesion (which one
of these patients had) and high-grade glioma (which the
other two had) [12]. One of the concerns with VTE in
patients who have cancer is not only the additional costs
associated with treating it but a significantly higher risk of
death within 1 year of the VTE episode (as compared
with those who have cancer but do not have a VTE
episode) [35]. This risk of death in cancer patients
experiencing a VTE may indicate the presence of
advanced and aggressive disease, which also requires
more aggressive therapies [34]. These likely cannot be
initiated until the risk of a further VTE is abated. An
advantage of using brain LITT is the ability to ambulate
early, which is standard prophylaxis against VTE.
As it relates to how costs were examined, calculated,
and evaluated (as identified in Sect. 2), we believe an
appropriate methodology was used for doing so that is
well-accepted in these types of analyses [36, 37].
These findings have relevance to recently introduced
initiatives by Medicare to provide less costly, better
quality care using ‘bundles of care.’ The BPCI program
recently introduced by Medicare in October 2015 is
being evaluated by thousands of providers across the
country in various conditions and in various episodes of
care [10]. This care entails acute hospital care and the
associated aftercare post-discharge (commonly 90 days
after hospital discharge). Since there appears to be a
shortening of the hospital stay and the potential for less
aftercare with LITT in patients with primary and metastatic brain cancers, LITT may hold promise; however,
more economic studies are needed to validate these
initial findings.
We believe this first look at actual cost data will
encourage more research into resource utilization for
craniotomy and LITT procedures. This research also supports the findings of prior published work [23]. However,
because patients would likely choose a minimally invasive
technology over an open procedure, there will probably
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never be a randomized study prospectively comparing
LITT to craniotomy. Additionally, since this is surgery
performed at the end of life, a randomized trial versus
craniotomy may also be difficult to initiate. While additional research into this area is needed, the preliminary
results of this study indicate trends that could guide the
development of larger studies.

5 Limitations
Limitations of this analysis include its retrospective nature
and the fact that it is a single-center study. It is unlikely
that a prospective randomized trial would be performed on
these patients, especially as the use of brain LITT in this
institution (Barnes Jewish Hospital) is focused on very
complex disease, in which the risk of complications
resulting from craniotomy are very high. The fact that this
is a single center at which brain LITT has been used regularly for several years demonstrates that good outcomes
can result from routine experiential use of a novel technology. A further limitation is that reimbursement values
converted to costs using national estimates of cost were
used; since this is an estimate for institutions in the St.
Louis area, it may not be reflective of the actual costs at
other sites. However, Medicare reimbursement (payments)
averages 5–7% below allowable Medicare costs for inpatient and outpatient services [38], 11.4% above costs for
IRFs [39], and 13.1% above costs for SNFs [40]; thus,
these cost estimates in aggregate are likely to be close to
actual costs. In addition, since records are not available of
the actual LOSs and care delivered in IRFs, SNFs, and
home healthcare for these patients, estimates were used.
The LOS estimate used in this analysis for SNFs (26 days)
is likely close to the actual LOS, based on published data
[41]. However, it is important to note that this analysis is
not a comparison of efficacy. While LITT may have a cost
advantage, assertions cannot be made at this time regarding
which modality is more effective in prolonging the life of
the patient.
It was assumed that patients discharged home and not
receiving additional care (e.g., SNF, rehabilitation, home
care) in both LITT and craniotomy did not have complications, but this may not have been the case. However, a
recent systematic review and meta-analysis comparing
LITT to craniotomy in patients with high-grade tumors in
or near areas of eloquence found that there were significantly lower complications and significantly more of the
tumor ‘excised’ with LITT [10]. As noted here, these
factors relate strongly to overall survival. These LITT
complication results also appear more favorable relative to
other treatment options for the types of patients studied,
such as stereotactic radiosurgery [42].
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Another limitation was that the VTE analysis was not
adjusted for known confounders of VTE and, therefore, the
reported VTE results should be viewed with caution. In
addition, the small sample size of the LITT metastatic
cancer group and its lower cost findings (vs. similar type
craniotomy patients) should be noted and viewed
accordingly.
The number of exclusions in the LITT group was 33
patients. As mentioned, these patients were excluded based
on the comparison of ‘like patients’ in each group, which
may have led to an unintended selection bias.
Another limitation of this analysis is that in calculating
the outliers, Grubb’s test was used with the assumption that
the data came from a normally distributed population.
Although it appears that the data had a normal distribution
and that exclusion of outliers was justified, increasing the
sample size in the LITT cohort may change the results.
There is heterogeneity in the data based on the use of
LITT and craniotomy as the surgical procedure for the
lesion location. In this particular practice, LITT is used for
deep-seated, DTA (due to the lesion’s location in or near
areas of eloquence) lesions. Conversely, lesions that are
more superficial in nature, and not adjacent to areas of
eloquence, are indicated for surgical incision via open
craniotomy. Based on the fact that higher complication
rates are commonly seen with deep-seated tumors (and
LITT was used more often in these type of patients when
taken as a percentage of all patients reported on in this
study, i.e., 21/30 = 70% vs. 65/340 = 19%), it was surprising to discover that the incidence and costs for postcare (where these complications would be treated) was
actually lower with LITT.

6 Conclusion
The use of brain LITT in very challenging anatomy
demonstrates (via statistical analysis) at worst cost equivalency to craniotomy (with craniotomy being used in cases
that are less challenging and potentially less costly) and at
best cost savings in metastatic disease. This may be due in
part to less care/lower costs for care post-discharge with
LITT. These other (non-hospital) care sites cost the system
significant additional monies and also delay the opportunity for these patients to go home—a significant consideration for patients with limited life expectancies. Lastly,
based on the increase in bundled episodes of care (e.g.,
coordinated acute and post-discharge care over a period of
time such as 90 days paid via a lump sum payment to all
providers involved in the care) for many different types of
care in the USA, LITT may be a viable alternative for this
type of care, potentially saving the healthcare system
money while delivering quality care.
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